Briefing
Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapy.
286 plasma samples from 86 people in the SCANDARE study were tested with an ultrasensitive tumor-informed whole-genome assay before surgery, during neoadjuvant therapy, and after surgery for stage II-III triple-negative breast cancer. A Personalis author affiliation is on the PubMed record.
- Design: Evidence level 3
- Assay: Personalis